Stay updated on CAB-AXL-ADC in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the CAB-AXL-ADC in Sarcoma Clinical Trial page.

Latest updates to the CAB-AXL-ADC in Sarcoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about the study of mecbotamab vedotin (BA3011) and its phases, while a new version number (v2.15.0) has been added.SummaryDifference15%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 15, 2025.SummaryDifference0.4%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
Stay in the know with updates to CAB-AXL-ADC in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CAB-AXL-ADC in Sarcoma Clinical Trial page.